News Column

LifeSci Advisors Initiates Coverage of Adocia

Apr 3 2013 12:00AM

Marketwire

LogoTracker

NEW YORK, NY -- (Marketwired) -- 04/03/13 -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Adocia (EURONEXT PARIS: ADOC), a biotechnology company focused on the development of best-in-class medicines from already approved therapeutic proteins using the BioChaperone technology. Adocia's lead product candidate, BioChaperone PDGF-BB, is a potential best-in-class drug for wound healing. It is slated to begin pivotal Phase III studies in 2013 in India for patients with diabetic foot ulcers. Adocia also has Phase II clinical programs for potential best-in-class fast-acting human insulin and insulin combinations. Moreover, Adocia has a partnership with Eli Lilly to develop an ultra-fast-acting Humalog, Lilly's leading insulin compound. This product is in Phase I.

"Adocia's BioChaperone technology has the potential to improve the efficacy, safety, and cost of a variety of protein therapeutics, including growth factors, insulin, and monoclonal antibodies," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The Company's innovative products could revolutionize the insulin delivery market, with a fast-acting and combination insulin products in development. The partnership with Eli Lilly, worth up to $165 million, provides important validation of the approach."

In February 2012, Adocia announced positive results from a Phase IIa clinical trial evaluating the safety and efficacy of HinsBet, a fast-acting human insulin for the treatment of type 1 diabetes. An optimized formulation is set to enter an additional Phase IIa trial, which is scheduled to launch in the second half of 2013. Adocia is also in pre-clinical development of a fast and slow-acting insulin combination therapy, and the data from pre-clinical models showed promise.

In addition to innovative insulin therapies, Adocia is developing a BioChaperone application aimed at the wound healing market. The planned Phase III program for BioChaperone PDGF-BB follows positive Phase II data. The Phase II trial enrolled 192 patients and revealed that BioChaperone PDGF-BB is non-inferior to the standard of care Regranex Gel. The non-inferior efficacy was achieved with one-third the total dose of PDGF, and with one application every two days versus every day for Regranex. The spray application method of PDGF-BB, when compared to Regranex Gel, results in lower cost, higher patient compliance, and improved safety. Given a more convenient dosing schedule, improved stability profile, and advantages over other growth factor treatments for wound healing, Adocia's improved, cost-effective treatment may provide a lucrative opportunity in both developed and emerging markets.

In a 35 page Initiation Report by LifeSci Advisors, we discuss the scientific basis of Adocia's BioChaperone technology, provide insight into clinical trial development, and give an in-depth overview of the diabetes and ulcer disease markets. This includes disease background and market information, current treatment options, current products and those in clinical development, and BioChaperone's strategy to compete in these markets. Also included are analyses of the competitive landscape of current therapies, Adocia's current financial position, and a discussion of their strategic partnership with Eli Lilly.

Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.



Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com


Adocia Contact:
Gerard Soula
Chairman and CEO
Phone: +33 4 72 610 610
Email: contactinvestisseurs@adocia.com






Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters